Cantor Fitzgerald Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its price target raised by equities researchers at Cantor Fitzgerald from $1,410.00 to $1,440.00 in a report issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 21.32% from the stock’s previous close.

Several other equities research analysts have also commented on LLY. Guggenheim upped their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 26th. HSBC boosted their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Berenberg Bank set a $1,400.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Trading Up 2.5%

LLY opened at $1,186.95 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a twelve month low of $783.85 and a twelve month high of $1,292.65. The stock has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 39.83, a P/E/G ratio of 1.42 and a beta of 0.46. The company has a 50-day simple moving average of $1,173.51 and a 200 day simple moving average of $1,094.59.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts predict that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last quarter. Insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently modified their holdings of the stock. Osbon Capital Management LLC purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $25,000. Basso Capital Management L.P. bought a new position in Eli Lilly and Company in the 4th quarter worth about $30,000. Maseco LLP raised its stake in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after purchasing an additional 28 shares in the last quarter. Aventus Investment Advisors Inc. raised its position in shares of Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after buying an additional 27 shares in the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. lifted its stake in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after purchasing an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Jim Cramer said he would favor Lilly over Novo Nordisk for a three- to five-year investment horizon, calling Lilly a high-quality company. The endorsement reinforces bullish sentiment around Lilly’s long-term growth prospects. Jim Cramer’s comparison of Novo Nordisk and Eli Lilly
• Positive Sentiment: Investors are increasingly looking beyond current blockbusters to retatrutide, Lilly’s next-generation triple-hormone obesity treatment. Reported trial weight loss has exceeded Zepbound’s results, and a potential FDA filing in early 2027 provides a major future catalyst. Lilly’s retatrutide drug data
• Positive Sentiment: Recent coverage highlights additional growth opportunities in oncology, immunology, neuroscience, and an oral GLP-1 candidate, Foundayo. Lilly also reported favorable Foundayo data versus oral semaglutide, potentially strengthening its competitive position in diabetes and obesity care. Foundayo clinical data
• Neutral Sentiment: Analysts remain divided: Lilly’s rapid revenue growth and pipeline support a premium valuation, but the stock trades near 40 times trailing earnings, leaving limited room for execution disappointments. Lilly’s growth and valuation analysis
• Negative Sentiment: New World Health Organization childhood-obesity guidelines could increase scrutiny of pediatric obesity treatments and create additional regulatory or market-access challenges for Lilly and Novo Nordisk. WHO childhood-obesity guidelines

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.